Source: International Congress 2019 – Biomarkers and beyond in idiopathic interstitial pneumonia
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Cameli (Siena, Italy), E. Bargagli (Siena, Italy), M. D'Alessandro (Siena, Italy), L. Bergantini (Siena, Italy), P. Sestini (Siena, Italy). Prognostic evaluation of alveolar concentration of nitric oxide, serum periostin and CD59 in patients with idiopathic pulmonary fibrosis. 2257

Member's Comments

No comment yet.

Related content which might interest you: Prognostic role of CCL18 serum concentrations in patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2007; 30: Suppl. 51, 574s Year: 2007 Increased alveolar concentration of nitric oxide is related to serum-induced lung fibroblast proliferation in scleroderma patients Source: Annual Congress 2009 - Cell biology of lung disease Year: 2009 Increased exhaled nitric oxide precedes lung fibrosis in a murine model of systemic sclerosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease Year: 2012 Evaluation of exhaled nitric oxide in idiopathic interstitial lung diseases Source: International Congress 2015 – IIPs: orphan Year: 2015 Bronchial and alveolar exhaled nitric oxide as a marker of systemic involvement in patients with Crohn‘s disease Source: Annual Congress 2011 - Role of the biomarkers in airway diseases Year: 2011 Measurement of alveolar nitric oxide in patients with lung cancer Source: Annual Congress 2012 - Screening, diagnosis, staging and treatment strategies for lung cancer Year: 2012 Effect of inhaled L-arginine on airway nitric oxide in cystic fibrosis patients Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle Year: 2005 Increased alveolar concentrations of exhaled nitric oxide (NO) are associated with lung affection in systemic sclerosis (SSc) Source: Eur Respir J 2005; 26: Suppl. 49, 543s Year: 2005 Antibiotic treatment decreases exhaled nitric oxide levels in cystic fibrosis patients Source: Eur Respir J 2004; 24: Suppl. 48, 384s Year: 2004 Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide Source: Eur Respir J 2007; 30: 26-30 Year: 2007 Value of induced sputum nitric oxide and 3-Nitrotyrosine(3NT) levels in differentiating obstructive and inflammatory diseases of lung Source: Eur Respir J 2003; 22: Suppl. 45, 268s Year: 2003 Nitric oxide production by the alveolar compartment of the lungs in cirrhotic patients Source: Eur Respir J 2009; 34: 138-144 Year: 2009 Exhaled nitric oxide in patients with idiopathic pulmonary fibrosis and pulmonary hypertension Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology? Year: 2008 Increased eNO and pulmonary iNOS expression in eNOS null mice Source: Eur Respir J 2003; 21: 770-773 Year: 2003 The source of exhaled nitric oxide does not correlate with clinical markers in interstitial lung disease Source: Annual Congress 2007 - Clinical aspects of interstitial lung disease Year: 2007 Glucocorticoid treatment reduces exhaled nitric oxide in cystic fibrosis patients Source: Eur Respir J 2001; 17: 1267-1270 Year: 2001 “T2-high” in severe asthma related to blood eosinophil, exhaled nitric oxide and serum periostin Source: Eur Respir J, 53 (1) 1800938; 10.1183/13993003.00938-2018 Year: 2019 Decreased BCL-2 expression in alveolar macrophages of patients with idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010 Elevated levels of alveolar nitric oxide in patients with inflammatory bowel disease Source: International Congress 2016 – Airway biomarkers Year: 2016 Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients Source: Eur Respir J 2008; 31: 815-821 Year: 2008